FEMSelect is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. The EnPlace procedure takes approximately 30 minutes. Its patented delivery system enables precise guidance, insertion, and deployment of the anchor unit, which is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization. EnPlace is FDA cleared and CE marked. The device is a combination of a Nitinol-based anchor, surgical sutures, and an innovative attachment method, and the surgery is conducted with no deep dissection or mesh. EnPlace has been tested in a human trial in Israel and is protected by global and U.S. patents.